Caleb Shumway, MD
Ophthalmology · Chula Vista, CANPI 1225698814
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $22,362 of the $28,505 with a category attached, or 78.4%. Bausch & Lomb Americas Inc. accounts for 75.4% of it on its own, with 19 other manufacturers making up the rest. 2025 is the largest year on record at $24,061, 9.1 times the $2,638 reported in 2023. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 108 payments — averaging $263.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$21K
- Nordic Pharma, Inc.$3K
- AbbVie$1K
- Biotissue Holdings Inc.$523
- Glaukos Corporation$331
- Tarsus Pharmaceuticals, Inc.$227
- plus $2K from 14 others
What the payments were for
- Consulting fees$22,36278%
- Travel & lodging$1,6406%
- Food & beverage$4,50316%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 32 | $21,479 |
| Nordic Pharma, Inc. | 1 | $3,206 |
| AbbVie | 15 | $1,214 |
| Biotissue Holdings Inc. | 18 | $523 |
| Glaukos Corporation | 5 | $331 |
| Tarsus Pharmaceuticals, Inc. | 4 | $227 |
| Alcon | 5 | $225 |
| Amgen | 3 | $191 |
| Carl Zeiss Meditec USA, Inc. | 1 | $190 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $178 |
| Sun Pharmaceutical Industries Inc. | 5 | $157 |
| Sight Sciences, Inc. | 3 | $140 |
| Mallinckrodt Hospital Products Inc. | 4 | $106 |
| Dompe US, Inc. | 2 | $80 |
| Lensar, Inc. | 1 | $80 |
| Oyster Point Pharma, Inc. | 2 | $58 |
| Nova Eye, Inc. | 1 | $44 |
| Astellas Pharma US Inc | 1 | $34 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Rxsight Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Lacrifill$3,206
- enVista MX60 IOL$1,926
- STELLARIS ELITE$1,926
- Trulign IOL$995
- Crystalens Accommodating IOL (AT-52AO)$995
- IC-8 Apthera IOL$931
- DURYSTA$243
- EQ Workplace$190
- XDEMVY$148
- TEPEZZA$142
- ENVISTA ENVY IOL$142
- TENEO$141
- iDoseTR$137
- Clareon$136
- ScoutPro Osmolarity System$121
- TEARCARE SYSTEM$100
- iStent infinite Trabecular Micro-Bypass System Model iS3$100
How this compares
$28,505 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 33 | $19,819 |
| Prednisolone Acetate | 80 | $3,109 |
| Ciprofloxacin Hcl | 47 | $823 |
| Ketorolac Tromethamine | 75 | $654 |
| Latanoprost | 40 | $282 |
| Ofloxacin | 23 | $183 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $1,214 | $19,81933 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Chula Vista
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
- Andrew MoshfeghiLos Angeles$895K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.